My C-section became a rotting flesh nightmare after docs used unsterile tools – I was in a wheelchair for 9 YEARS

KELLY Simmons was left wheelchair-bound for nine years after a flesh-eating bug infected her C-section scar, as a result of ...
Yahoo Finance

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE)-- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
The News-Gazette

Pet Talk | When skin infections keep coming back: Pyoderma in dogs and cats

Dr. Clarissa Souza, a board-certified veterinary dermatologist and head of the dermatology and otology service at the University of Illinois Veterinary Teaching Hospital in Urbana. Dr. Clarissa Souza, ...
CNBC

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. After the ...
Benzinga.com

InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder

InflaRx N.V. (NASDAQ: IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led ...
Seeking Alpha

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Entrepreneur

I Run a Portfolio of High-Growth Companies — This Practice Makes It All Possible

Anchor your business to a stubborn, real-world problem customers cannot ignore. Replace hustle with systems that standardize decisions, data flow and accountability. Ambition isn’t what holds ...
The Motley Fool

Why Structure Therapeutics Stock Doubled and Then Some on Monday

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...
STAT

Structure reports promising weight loss outcomes with obesity drug, but side effect questions loom

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Structure Therapeutics ...
Women's Wear Daily

Nike’s Structure Plus Is the Running Shoe That Lets You Eat Your Dessert and Vegetables

Just two of the nine shoes leading Nike’s reorganized running lineup have yet to release. Both of those come from the Structure franchise, and one has been confirmed for an early 2026 release. The ...
KREM

Family pleads for help to save Spokane father battling rare, excruciating disease

SPOKANE, Wash. — A family is pleading for help to save the life of Ryan Becker, who is fighting an extremely rare and devastating illness known as Pyoderma Gangrenosum, a condition described by ...
Nasdaq

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...